Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023
Kalorama Information’s Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts based recent market conditions. For each company, the report provides:
- R&D Spending
- Geographic Breakout of Revenues
- Performance of Specific Products
- Performance by Drug Category
- Late-Stage Pipeline
- Projections of Revenues to 2023
In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades.
The companies included in the study are:
Merck & Co., inc.
Johnson & johnson
Astra Zeneca plc
Eli Lilly and Company
Teva Pharmaceutical Industries, Ltd.
Bristol-myers Squibb Company
Takeda Pharmaceutical co., LTD
Boehringer Ingelheim gmbh
For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical, including biopharmaceutical products. The market excludes consumer pharmaceuticals; diagnostics; devices; chemicals; agriculture; and animal health. Strategic acquisitions and partnerships with biotech companies have allowed traditional pharmaceutical companies an opportunity to become diverse in pipelines and product offerings. Companies like Amgen, which specialize in biotechnology, now compete with a growing number of what the industry has once considered to be the traditional pharmaceutical company, This is a trend expected to continue to grow as interest in the small biotechnology focused companies continue to be acquired by the Pfizer’s, Novartis’ and Roche’s of the industry